Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 11, 2024
Graduating resident and fellow readiness for general urologic practice during the COVID-19 pandemic: A survey-based assessment of trainees and program directorsKyle Waisanen, Finn Hennig, Ellen Lutnick, et al.
The Journal of Urology|December 17, 2013
Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsyK Kent Chevli, Michael Duff, Peter Walter, et al.
Clinical Genitourinary Cancer|August 2, 2024
PSA Levels and Mortality in Prostate Cancer PatientsDietrich von Kuenssberg Jehle, Nam Nguyen, Michael A Garza, et al.
The Prostate|September 19, 2015
PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsyAhmed Elshafei, K Kent Chevli, Ayman S Moussa, et al.
Clinical Genitourinary Cancer|July 31, 2025
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II StudyNeal D Shore, K Kent Chevli, Daniel Saltzstein, et al.
BJUI Compass|March 14, 2024
Optilume drug-coated balloon for anterior urethral stricture: 2-year results of the ROBUST III trialMaia E VanDyke, Allen F Morey, Karl Coutinho, et al.
The Journal of Urology|December 2, 2021
One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume® Drug-Coated Balloon for Anterior Urethral StricturesSean P Elliott, Karl Coutinho, Kaiser J Robertson, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
The Journal of Urology|April 28, 2026
Non-Invasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRIJeffrey J Tosoian, Jacob I Meyers, Bradley Moore, et al.
Pageof 2